Literature DB >> 30363418

Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.

Matej Skorvanek1,2, Pablo Martinez-Martin3, Norbert Kovacs4,5, Mayela Rodriguez-Violante6, Jean-Christophe Corvol7, Pille Taba8, Klaus Seppi9, Oleg Levin10, Anette Schrag11, Thomas Foltynie12, Mario Alvarez-Sanchez13, Tomoko Arakaki14, Zsuzsanna Aschermann4, Iciar Aviles-Olmos12, Eve Benchetrit7, Charline Benoit7, Alberto Bergareche-Yarza15, Amin Cervantes-Arriaga16, Anabel Chade17, Florence Cormier7, Veronika Datieva10, David A Gallagher18, Nelida Garretto14, Zuzana Gdovinova1,2, Oscar Gershanik17, Milan Grofik19, Vladimir Han1,2, Jing Huang20, Liis Kadastik-Eerme8, Monica M Kurtis21, Graziella Mangone7, Juan Carlos Martinez-Castrillo22, Amelia Mendoza-Rodriguez23, Michal Minar24, Henry P Moore25, Mari Muldmaa26, Christoph Mueller9, Bernadette Pinter9, Werner Poewe9, Karin Rallmann8, Eva Reiter9, Carmen Rodriguez-Blazquez3, Carlos Singer25, Barbara C Tilley20, Peter Valkovic24, Christopher G Goetz27, Glenn T Stebbins27.   

Abstract

BACKGROUND: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a newly developed tool to assess Parkinson's disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS-UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD.
METHODS: For this cross-sectional study, demographic data and MDS-UPDRS scores were collected, including HY stage. Subscores on MDS-UPDRS Parts I through IV were analyzed using 1-way analyses of variance for each HY stage and in 5-year increments of disease duration. Part III (motor assessment) scores were analyzed separately for on and off states.
RESULTS: The mean age of the 3206 patients was 65.8 ± 10.6 years, 53.3% were men, the mean disease duration was 11.5 ± 4.6 years, and the median HY stage was 2 (range, 0-5); 2156 patients were examined in an on state and 987 were examined in an off state. Scores for all MDS-UPDRS parts increased significantly through HY stages 1 through 5, with an average increase of 3.8, 7.7, 14.6, and 2.0 points consecutively for parts I through IV, respectively. For the 5-year increments of disease duration, MDS-UPDRS subscores increased by an average of 1.6, 3.3, 4.2, and 1.4 points consecutively for parts I through IV, respectively. This increase was significant only during the first 15 years of disease for all 4 parts, including part III scores evaluated in both on and off states.
CONCLUSIONS: MDS-UPDRS scores for all 4 parts increase significantly with every HY stage and also with 5-year increments of disease duration in the first 15 years of the disease.

Entities:  

Keywords:  Hoehn and Yahr; Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS); Parkinson's disease; disease duration; scale

Year:  2017        PMID: 30363418      PMCID: PMC6174385          DOI: 10.1002/mdc3.12476

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  19 in total

1.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.

Authors:  Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

2.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

3.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

4.  Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT.

Authors:  W Staffen; A Mair; J Unterrainer; E Trinka; G Ladurner
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

5.  The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system.

Authors:  K Ray Chaudhuri; A Sauerbier; J M Rojo; K Sethi; A H V Schapira; R G Brown; A Antonini; F Stocchi; P Odin; K Bhattacharya; Y Tsuboi; K Abe; A Rizos; Carmen Rodriguez-Blazquez; P Martinez-Martin
Journal:  Parkinsonism Relat Disord       Date:  2015-01-05       Impact factor: 4.891

Review 6.  The natural history of Parkinson's disease.

Authors:  W H Poewe; G K Wenning
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

7.  Factor analysis of Parkinson's impairment. An evaluation of the final common pathway.

Authors:  N C Reynolds; G K Montgomery
Journal:  Arch Neurol       Date:  1987-10

8.  Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Authors:  Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry P Moore; Mayela Rodriguez-Violante; Carlos Singer; Barbara C Tilley; Jing Huang; Glenn T Stebbins; Christopher G Goetz
Journal:  J Neurol       Date:  2012-08-05       Impact factor: 4.849

9.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

10.  Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype.

Authors:  Brook Galna; Sue Lord; David J Burn; Lynn Rochester
Journal:  Mov Disord       Date:  2014-12-27       Impact factor: 10.338

View more
  20 in total

1.  Dysphagia Presentation, Airway Invasion, and Gender Differences in a Clinically Based Sample of People with Parkinson's Disease.

Authors:  Matthew Dumican; Christopher Watts; Teresa Drulia; Yan Zhang
Journal:  Dysphagia       Date:  2022-07-09       Impact factor: 3.438

2.  World guidelines for falls prevention and management for older adults: a global initiative.

Authors:  Manuel Montero-Odasso; Nathalie van der Velde; Finbarr C Martin; Mirko Petrovic; Maw Pin Tan; Jesper Ryg; Sara Aguilar-Navarro; Neil B Alexander; Clemens Becker; Hubert Blain; Robbie Bourke; Ian D Cameron; Richard Camicioli; Lindy Clemson; Jacqueline Close; Kim Delbaere; Leilei Duan; Gustavo Duque; Suzanne M Dyer; Ellen Freiberger; David A Ganz; Fernando Gómez; Jeffrey M Hausdorff; David B Hogan; Susan M W Hunter; Jose R Jauregui; Nellie Kamkar; Rose-Anne Kenny; Sarah E Lamb; Nancy K Latham; Lewis A Lipsitz; Teresa Liu-Ambrose; Pip Logan; Stephen R Lord; Louise Mallet; David Marsh; Koen Milisen; Rogelio Moctezuma-Gallegos; Meg E Morris; Alice Nieuwboer; Monica R Perracini; Frederico Pieruccini-Faria; Alison Pighills; Catherine Said; Ervin Sejdic; Catherine Sherrington; Dawn A Skelton; Sabestina Dsouza; Mark Speechley; Susan Stark; Chris Todd; Bruce R Troen; Tischa van der Cammen; Joe Verghese; Ellen Vlaeyen; Jennifer A Watt; Tahir Masud
Journal:  Age Ageing       Date:  2022-09-02       Impact factor: 12.782

3.  Association of Total Bilirubin with Motor Signs in Early Parkinson's Disease in LRRK2 Variant Carriers.

Authors:  Danial Kazemi; Hamed Hajishah; Amir Shayan Chadeganipour
Journal:  J Mol Neurosci       Date:  2022-09-20       Impact factor: 2.866

4.  An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.

Authors:  Florence Véronneau-Veilleux; Philippe Robaey; Mauro Ursino; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-21       Impact factor: 2.745

Review 5.  Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.

Authors:  Upasana Ganguly; Sukhpal Singh; Soumya Pal; Suvarna Prasad; Bimal K Agrawal; Reena V Saini; Sasanka Chakrabarti
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

6.  Alexithymia Is Associated with Reduced Quality of Life and Increased Caregiver Burden in Parkinson's Disease.

Authors:  Martin Klietz; Theresa Schnur; Simon C Drexel; Florian Lange; Lejla Paracka; Meret K Huber; Dirk Dressler; Günter U Höglinger; Florian Wegner
Journal:  Brain Sci       Date:  2020-06-24

7.  Plasma VCAM1 levels correlate with disease severity in Parkinson's disease.

Authors:  Caroline Perner; Florian Perner; Nayana Gaur; Silke Zimmermann; Otto W Witte; Florian H Heidel; Julian Grosskreutz; Tino Prell
Journal:  J Neuroinflammation       Date:  2019-05-08       Impact factor: 8.322

8.  Contrast and Homogeneity Feature Analysis for Classifying Tremor Levels in Parkinson's Disease Patients.

Authors:  Guillermina Vivar; Dora-Luz Almanza-Ojeda; Irene Cheng; Juan Carlos Gomez; J A Andrade-Lucio; Mario-Alberto Ibarra-Manzano
Journal:  Sensors (Basel)       Date:  2019-05-04       Impact factor: 3.576

9.  Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study.

Authors:  Zhenxin Zhang; Jian Wang; Shengdi Chen; Chunfeng Liu; Baorong Zhang; Rong Peng; Shenggang Sun; Xiangru Sun; Gang Zhao; Qiumin Qu; Yansheng Li; Suiqiang Zhu; Xiaoping Pan; Ming Shao; Yanping Wang
Journal:  Transl Neurodegener       Date:  2018-12-06       Impact factor: 8.014

10.  Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease.

Authors:  Brenna A Cholerton; Kathleen L Poston; Laurice Yang; Liana S Rosenthal; Ted M Dawson; Alexander Pantelyat; Karen L Edwards; Lu Tian; Joseph F Quinn; Kathryn A Chung; Amie L Hiller; Shu-Ching Hu; Thomas J Montine; Cyrus P Zabetian
Journal:  J Clin Exp Neuropsychol       Date:  2021-08-06       Impact factor: 2.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.